Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	84
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	72
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events	51
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	44
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	44
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	41
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	35
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	32
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	32
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	28
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	28
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	25
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas	24
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	21
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	21
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	19
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	19
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study	18
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	17
Progress in histology specific treatments in soft tissue sarcoma	17
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis	17
Current management of familial adenomatous polyposis	16
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	15
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	15
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	15

Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	14
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	13
The importance of autophagy in multiple myeloma	13
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study	13
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	13
Elacestrant in metastatic breast cancer: current advancements and future perspectives	13
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	13
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	13
Early detection of hepatocellular carcinoma: roadmap for improvement	13
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	13
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	12
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	12
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
Targeting GPRC5D in multiple myeloma	12
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors	12
Deciding individual treatment for primary retroperitoneal sarcoma	12
The trend toward more target therapy in pancreatic ductal adenocarcinoma	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
Nivolumab plus ipilimumab in malignant pleural mesothelioma	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma	11
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	11
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	11
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	11
Management of breast cancer diagnosed during pregnancy: global perspectives	11
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	11
PROTACs in action: a novel strategy for pancreatic cancer	11
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Emerging treatment options for prostate cancer	10
Interventions to reduce the risk of side-effects of cancer treatments in childhood	10
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	10
Novel breakthroughs in advanced prostate cancer management	10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	10
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	10
Benign and malignant cardiac masses: long-term outcomes after surgical resection	10
Drugging the DNA damage response in the clinic: going beyond PARP	10
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	10
Upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	10
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9
The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	9
Oligometastases in head and neck squamous cell carcinoma patients	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9

Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
CRISPR–mRNA synergy: toward adaptive cancer immunotherapy	9
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing	9
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
ESMO 2025 and new therapies in breast cancer: does society always benefit?	8
Venetoclax and beyond: New Horizons in CLL and AML therapy	8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	8
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis	8
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	7
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	7
Is the ketogenic diet still controversial in cancer treatment?	6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	6
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	6
Medullary thyroid carcinoma: a narrative historical review	6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	6
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
Future directions for antibody-drug conjugates in urothelial cancer	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	6
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	6
Clear cell sarcoma: state-of-the art and perspectives	5
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs	5
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	5
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
Current and emerging treatment options for BRAFV600-mutant melanoma	5
Primary site and treatment impact in unresectable metastatic colorectal cancer	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	5
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
The role of planetary health in urologic oncology	5
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	5
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
Relugolix in the management of prostate cancer	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	5
Harnessing the power of artificial intelligence for clinical trials in cancer	5
How can we address the challenge of distant metastases in HNSCC prognosis?	5
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5

Cancer immunotherapy efficacy and machine learning	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	5
Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies	5
Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment	5
Integrating PET/CT into breast cancer care: a review of recent developments	5
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
The multidisciplinary management of locally advanced rectal cancer	5
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction	5
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	5
Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database	4
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review	4
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma	4
The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management	4
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized cont	4
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care	4
Medical imaging and multimodal artificial intelligence models for streamlining and enhancing cancer care: opportunities and challenges	4
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment	4
A meta-analysis of UCA1 accuracy in the detection of bladder cancer	4
Prognostic value of the nodal yield in oral squamous cell carcinoma: a systematic review and meta-analysis	4
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review	4
Implementation of a CAR-T cell therapy program in India	4
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis	4
The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis	4
Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma	4
Understanding the link between aspartame and cancer	4
Liposomal nanomedicine in cancer therapy: advances in drug delivery	4
Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes	4
A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores	4
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial	4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma	4
Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis	4
Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis	4
Burden trends and risk factors for prostate cancer from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021	4
Quality of life in ovarian cancer patients receiving maintenance therapy with bevacizumab versus PARPi: a network meta-analysis	4
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy	4
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer	4
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab	4
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer	4
Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer	4
G-CSF for managing venetoclax-related neutropenia in acute myeloid leukemia	4
Advances and future directions in radiopharmaceutical delivery for cancer treatment	4
Targeted therapies in advanced biliary malignancies: a clinical review	4
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges	4
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?	4
Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches	4
Factors influencing survival in metastatic castration-resistant prostate cancer therapy	4
Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma	4
Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma	4
Hot topics in renal cancer pathology: implications for clinical management	4
The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions	4
Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis	4
Increasing the accuracy of colorectal cancer screening	3
Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors	3
Implementing machine learning to predict survival outcomes in patients with resected pulmonary large cell neuroendocrine carcinoma	3
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2 -mutant NSCLC: a bench-to-bedside review	3
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer	3
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC	3
Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challenges	3
New horizons for hope of cure in acute myeloid leukemia through immunotherapy: a narrative review	3
Chronic lymphocytic leukaemia in the Middle East: a subgroup analysis from the CREEK study on treatment patterns and outcomes	3
Current evidence and future directions in the surveillance of HPV-positive oropharyngeal carcinoma	3
Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review	3
Novel therapies for metastatic prostate cancer	3
The role of PSMA PET/CT imaging in identifying low-risk prostate cancer candidates for active surveillance after biopsy	3
Re-irradiation for recurrent/progressive pediatric brain tumors: from radiobiology to clinical outcomes	3
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies	3
Contemporary management of diffuse large B-cell lymphoma in Japan	3
Clinical management of oligoprogressive renal cell carcinoma	3
Overview and recent advances in incidental meningioma	3
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma	3
Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what’s new in 2025?	3
Future investigative directions for novel therapeutic targets in head and neck cancer	3
The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors	3
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis	3
The new insights of surgery for locally advanced head and neck cancer	3
The prognostic significance of lymph node metastases characteristics in papillary thyroid carcinoma: a scoping review	3
Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B?	3
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment	3
Current usage of pembrolizumab in triple negative breast cancer (TNBC)	3
The clinical utility of molecular residual disease testing in early-stage breast cancer	3
Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives	3
Olaparib targets Ubiquitin D to promote autophagy in hepatocellular carcinoma by regulating glutamine metabolism	3
Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer	3
PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes	3
Opportunities and challenges in the clinical application of anticancer virotherapy	3
A clinical visualization model for predicting distant metastasis and prognostic outcomes in mucinous adenocarcinoma of the appendix: a SEER database study	3
The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis	3
Emerging strategies and advances in the management of sinonasal carcinoma	3
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors	3
Melanoma neoadjuvant treatment: review and update of recent trials	3
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a system	3
Medullary thyroid carcinoma	3